Loading company…
Shield Diagnostics develops rapid molecular tests for infectious diseases and antibiotic susceptibility.
Shield Diagnostics develops molecular testing through its Target-X platform to identify infectious agents and antibiotic susceptibility genes. Its Target-NG product assesses ciprofloxacin sensitivity in N. gonorrhoeae infections. Founded in 2016 by Fred Turner and Sam Parlett, the company is based in California, US.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in